Clinical Report: Impact of Benign Hematology on Neutropenia in Cancer Patients
Overview
This report discusses a case of grade 3 neutropenia in a patient undergoing immune checkpoint inhibitor therapy, highlighting the potential role of benign ethnic neutropenia (BEN) in the patient's condition. The findings underscore the importance of recognizing benign hematological phenomena in the management of cancer patients.
Background
Neutropenia is a common complication in cancer patients, often resulting from treatment with cytotoxic agents. Understanding the underlying causes of neutropenia is crucial for appropriate management, especially in patients receiving immune checkpoint inhibitors, where isolated neutropenia can occur. Misclassification of benign conditions as treatment-related can lead to unnecessary interventions and anxiety.
Data Highlights
No specific numerical data was provided in the source material.
Key Findings
['The patient developed grade 3 neutropenia after three months of immune checkpoint inhibitor therapy.', 'Previous reports indicated occasional asymptomatic neutropenia in patients of African ancestry, suggesting a benign etiology.', 'Neutropenia was ruled out as a side effect of the immune checkpoint inhibitor due to its low associated risk.', 'Comprehensive assessments, including blood tests, ruled out other causes of neutropenia such as infections and nutritional deficiencies.', 'Recognition of benign ethnic neutropenia (BEN) is essential to avoid misinterpretation of neutrophil counts in patients of African descent.']Clinical Implications
Healthcare providers should consider benign ethnic neutropenia in patients of African ancestry presenting with neutropenia, particularly when other causes have been excluded. Awareness of this condition can prevent unnecessary treatment modifications and improve patient management.
Conclusion
The case illustrates the critical need for awareness of benign hematological conditions in cancer care, particularly in diverse populations. Proper identification of neutropenia etiology can enhance treatment decisions and patient outcomes.
References
- Elhadad et al., 2022 -- Diagnosis of BEN/DANC in Neutropenic Patients
- Gay et al., 2023 -- Immune Checkpoint Inhibitors and Neutropenia
- Merz et al., 2023 -- Neutrophil Count Variability in Cancer Patients
- Awan et al., 2021 -- Normal Ranges for Absolute Neutrophil Count
- Holland & Gallin, 2022 -- Neutropenia in Cancer Therapy
- Berliner, 2022 -- Understanding Neutropenia Etiologies
- jadpro — The Use of Remote Monitoring in Care Management for Bone Marrow Transplant Patients
- Archives of Gynecology and Obstetrics — The adverse prognostic impact of reduced chemotherapy dose intensity appears attenuated in early breast cancer patients with treatment-relevant neutropenia: a retrospective cohort study
- Open Forum Infectious Diseases — The Diagnostic and Therapeutic Limitations of Chest X-Rays in Febrile Neutropenic Patients with Hematological Disorders
- Bone Marrow Transplantation — Key Takeaways on Bone Marrow Failure Syndromes from the 3rd ESH-EBMT-EHA-IPIG Translational Research Conference
- The Use of Remote Monitoring in Care Management for Bone Marrow Transplant Patients
- The adverse prognostic impact of reduced chemotherapy dose intensity appears attenuated in early breast cancer patients with treatment-relevant neutropenia
- The Diagnostic and Therapeutic Limitations of Chest X-Rays in Febrile Neutropenic Patients with Hematological Disorders
- Key Takeaways on Bone Marrow Failure Syndromes from the 3rd ESH-EBMT-EHA-IPIG Translational Research Conference
- Grade 2 Neutrophil Count Decreased, CTCAE
- Development of Duffy Null–Specific Absolute Neutrophil Count Reference Ranges
- Cancer Trial Eligibility and Therapy Modifications for Individuals With Duffy Null–Associated Neutrophil Count
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
